He will lead CD36 development programs in various chronic inflammation-based diseases such as dry age-related macular degeneration, atherosclerosis and non-alcoholic steatohepatitis.
Chipperton is a serial life sciences entrepreneur, and comes with a proven track-record, most notably as 2008 co-founder and CEO of Profound Medical Inc., where in a four-year span he raised more than CDN 16m of venture capital financing, and the company subsequently went public in 2015, on the TSX Venture exchange (TSX: PRN) (OTCQX: PRFMF).
He currently sits on the boards of Intronix and Angel Investors Ontario. He is deeply experienced in rapidly transitioning academic research into established, well-financed clinical stage companies.
Mperia Therapeutics is the CD36 Therapeutics company which focuses on macrophage-driven inflammation.
The technology basis resides in highly specific CD36 receptor cyclic peptides which modulate the inflammasome in addition to modifying macrophages' metabolic dysfunction with outstanding anti-inflammatory response.
Mperia holds exclusive rights to various highly efficacious CD36 receptors ligands against dAMD and atherosclerosis.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007